Boundless Bio, Inc. (BOLD) is a pre-revenue clinical-stage oncology company. Under the liquidation lens as of March 31, 2026, the dominant asset is the cash and short-term investment portfolio: $17.5M cash equivalents plus $75.4M short-term available-for-sale securities plus $0.6M restricted cash, totaling approximately $93.5M in liquid financial assets recoverable at or near face value. Prepaid and other current assets of $1.8M recover at a modest haircut; PP&E net of $2.9M (gross $8.2M, accumulated depreciation $5.2M) recovers at perhaps 50%, yielding roughly $1.5M. The operating right-of-use asset of $42.8M carries zero liquidation value as the underlying operating lease obligation stays at face value on the liability side. Total reported assets of $141.0M collapse to a recoverable pool of approximately $95-96M under standard liquidation haircuts. Against this, total liabilities of $54.6M at face value include: current operating lease liability of $3.3M, noncurrent operating lease liability of $45.0M (the 2024 Lease with undiscounted future payments of $68.1M as of March 31, 2026), accounts payable and accrued liabilities of $5.7M, and employee-related current liabilities of $0.6M. The noncurrent operating lease liability is the critical liability overhang. MFFAIS reports CLV/LLV/OLV of negative $37.1M, consistent with the asymmetric treatment: the ROU asset haircuts to zero while the lease liability remains at face. However, this analysis is complicated by a material subsequent event: on April 13, 2026, the company negotiated early termination of the 2024 Lease effective May 31, 2026, paying the landlord $10.0M cash and forfeiting a $0.5M security deposit. This extinguishes the $45.0M noncurrent operating lease liability (and associated $3.3M current portion) post-balance-sheet-date, at a cash cost of $10.5M total. Post-termination, the lease liability stack collapses dramatically, and the company simultaneously entered a short-term 12-month replacement lease at approximately $56K/month with a $77K deposit—a de minimis new obligation. The as-reported balance sheet therefore overstates liabilities (in a liquidation context) relative to the post-April 13 position, but also overstates liquid assets by approximately $10.5M that was paid out in April 2026. Net effect: the lease termination is approximately NPV-neutral to modestly positive for liquidation recovery, eliminating a long-dated lease obligation at a significant but manageable cash cost. Accumulated deficit stands at $273.2M; operating burn is approximately $15.0M per quarter (cash basis). Management guides runway into second half of 2028 on $92.8M cash and investments at period end, before the $10.5M lease termination payment. No debt, no pension, no convertible notes. The balance sheet is clean except for the lease structure. Recovery posture is marginally negative to near breakeven under liquidation, consistent with MFFAIS CLV of negative $37.1M applied to the as-reported March 31 balance sheet.
▼ Community Notes